Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.88 - $1.73 $1.46 Million - $2.87 Million
-1,660,288 Reduced 33.53%
3,291,135 $2.9 Million
Q1 2022

May 16, 2022

BUY
$1.14 - $2.09 $1.06 Million - $1.94 Million
926,485 Added 23.02%
4,951,423 $6.14 Million
Q4 2021

Feb 14, 2022

BUY
$1.67 - $2.76 $334,000 - $552,000
200,000 Added 5.23%
4,024,938 $7.85 Million
Q3 2021

Nov 15, 2021

SELL
$2.62 - $3.45 $670,025 - $882,285
-255,735 Reduced 6.27%
3,824,938 $10.5 Million
Q2 2021

Aug 17, 2021

SELL
$1.96 - $3.15 $189,110 - $303,927
-96,485 Reduced 2.31%
4,080,673 $12.9 Million
Q1 2021

May 17, 2021

BUY
$1.89 - $2.96 $2.74 Million - $4.3 Million
1,452,158 Added 53.29%
4,177,158 $8.9 Million
Q4 2020

Feb 16, 2021

BUY
$0.65 - $1.94 $1.77 Million - $5.29 Million
2,725,000 New
2,725,000 $5.29 Million
Q3 2019

Nov 14, 2019

SELL
$0.46 - $1.29 $309,868 - $868,980
-673,628 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$0.54 - $1.33 $728,156 - $1.79 Million
-1,348,438 Reduced 66.69%
673,628 $0
Q1 2019

May 15, 2019

BUY
$1.1 - $1.76 $602,962 - $964,740
548,148 Added 37.19%
2,022,066 $2.59 Million
Q4 2018

Feb 14, 2019

SELL
$1.28 - $2.24 $256,000 - $448,000
-200,000 Reduced 11.95%
1,473,918 $2.21 Million
Q3 2018

Nov 14, 2018

BUY
$1.23 - $1.49 $371,491 - $450,018
302,026 Added 22.02%
1,673,918 $2.43 Million
Q2 2018

Aug 13, 2018

BUY
$0.85 - $1.5 $105,944 - $186,961
124,641 Added 9.99%
1,371,892 $1.88 Million
Q4 2017

Feb 12, 2018

BUY
$0.72 - $2.03 $135,982 - $383,395
188,865 Added 17.84%
1,247,251 $1.38 Million
Q3 2017

Nov 09, 2017

BUY
$1.54 - $1.85 $1.63 Million - $1.96 Million
1,058,386
1,058,386 $1.69 Million

Others Institutions Holding VTGN

About VistaGen Therapeutics, Inc.


  • Ticker VTGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 206,836,000
  • Market Cap $720M
  • Description
  • VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...
More about VTGN
Track This Portfolio

Track Sphera Funds Management Ltd. Portfolio

Follow Sphera Funds Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Sphera Funds Management Ltd. with notifications on news.